-
Roche's new crown oral drug failed phase II clinical progress and how is the clinical progress of the other 4 companies
Time of Update: 2021-11-16
Recently, Roche and Atea Pharmaceuticals announced that their new crown oral drug AT-527 global phase II trial MOONSONG did not meet the primary endpoint .
The clinical failure of Roche/Atea's new crown oral drug is right.
-
The IND of APL-1202 and BeiGene's combined neoadjuvant treatment of MIBC is approved by CDE
Time of Update: 2021-11-16
Shanghai, October 13, 2021/PRNewswire/ - Yahong Pharmaceutical announced today that its oral drug APL-1202 and BeiGene Baizean® (tislelizumab) combined with neoadjuvant treatment of muscle invasion The New Drug Clinical Research Application (IND) for bladder cancer (MIBC) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China .
-
First in class oral complement C5aR inhibitor approved in Japan
Time of Update: 2021-11-16
Avacopan uses a novel and highly targeted mechanism of action in the treatment of ANCA-related vasculitis and other complement-driven autoimmune and inflammatory diseases .
On July 6 this year, ChemoCentryx announced that the PDUFA target date for avacopan's new drug application in the United States has been extended to October 7, 2021 .
-
"Yiwu Market" among pharmaceutical companies?
Time of Update: 2021-11-16
According to the agreement, Zai Lab will obtain the exclusive developer and commercialization rights for Retifanlimab blood and solid tumor indications in Greater China (including Hong Kong, Macau and Taiwan), and Incyte will receive a down payment of US$17.
-
AbbVie JAK inhibitor reaches two primary endpoints of Phase 3 clinical trials
Time of Update: 2021-11-16
html[2] AbbVie's upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis.
-
FDA Approves New Coronavirus Vaccine "Mixed Fighting" Enhanced Vaccination Program
Time of Update: 2021-11-16
The authorization for Moderna's new crown vaccine allows a single dose of Moderna booster vaccine (dose halved) in people who have completed two doses of vaccination for at least 6 months .
-
CD73 monoclonal antibody!
Time of Update: 2021-11-16
After this clinical approval, Jacos Pharmaceuticals will start a phase 1/2a clinical trial for patients with solid tumors in the United States .
-
16 exclusive Chinese patent medicines to grab the TOP20!
Time of Update: 2021-11-16
Pediatric Chinese patent medicine increased by 87%, Yang Zijiang became the "big brother"Sales of proprietary Chinese medicines in public hospitals in key cities (unit: ten thousand yuan)Source: Mi Nei. com's key city public hospital terminal competition patternAffected by the epidemic and policies, the market size of proprietary Chinese medicines in public hospitals in key cities will decline significantly in 2020, of which Q1 will decline by nearly 30% in 2020 .
-
Winbond Health's wholly-owned subsidiary methylprednisolone sodium succinate for injection passed the consistency evaluation
Time of Update: 2021-11-16
On October 26, Winbond Health issued an announcement stating that its wholly-owned subsidiary Winbond Pharmaceuticals had recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for injection of methylprednisolone sodium succinate.
-
Eleven Years of "Pharmaceuticals": Online Digital Drive of Pharmaceuticals, Business Empowerment, Helping Pharmaceutical Enterprises to Transform and Upgrade
Time of Update: 2021-11-16
Provide accurate matching services and build a supply-demand docking platformBuild a smart medicine business school and build a knowledge sharing ecosystem in the pharmaceutical industryAt the beginning of 2021, "Pharmaceutical Online" relied on the rich experience accumulated by the website platform in the past 11 years to integrate resources of existing conference products and upgraded to become the "Intelligent Pharmacy Business School" to create social, learning, and sharing scenarios for the majority of pharmaceutical industry professionals.
-
Chengdu Beite's 3 major new products will be approved
Time of Update: 2021-11-16
Recently, Chengdu Better (including its subsidiaries) has 3 new generic drugs that have been classified for production and entered the administrative approval stage, namely Futhiaxetine Hydrobromide Tablets, Lenvatinib Mesylate Capsules and Ipratropium Bromide.
-
Director and Deputy General Manager Li Huajun of Si Taili resigned
Time of Update: 2021-11-16
On October 11, Stellite issued an announcement stating that the board of directors had recently received a written resignation report from the company’s director and deputy general manager, Mr.
After resignation, he will not hold any position in the company.
-
Data of Merck's pembrolizumab for adjuvant therapy after complete resection of high-risk stage II melanoma patients announced
Time of Update: 2021-11-16
, Kenilworth, New Jersey, USA) first announced its PD-1 inhibitor pembrolizumab[1] Data from the Phase III clinical trial KEYNOTE-716 for the adjuvant treatment of patients with high-risk phase II melanoma after complete resection .
-
The development of PROTAC drugs is being developed at the time, and Baekje and Haisco continue to make efforts
Time of Update: 2021-11-15
Unlike traditional small molecule drugs, PROTAC does not require long-term and high-strength binding to the target protein to capture the protein and degrade it.
-
The third-generation EGFR-TKI vomitinib was successfully studied in the first-line treatment of advanced NSCLC
Time of Update: 2021-11-15
(hereinafter referred to as "Ailisi", stock code: 688578) announced its independent research and development of the third representative skin growth factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Ivesa® (Vormetinib mesylate, hereinafter referred to as "Vormetinib") is the first-line treatment for locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations The national multicenter, randomized controlled, double-blind phase III clinical study (FURLONG) reached the primary endpoint of progression-free survival (PFS).
-
The pattern of the pharmaceutical industry is about to change, and we are optimistic about these configurations in innovative drugs and the industry chain.
Time of Update: 2021-11-15
According to the data of the three quarterly reports released by Tiger Medicine, its revenue, profit attributable to the parent, and net profit deducting non-attributable to the parent in the first three quarters have increased by approximately 48%, 35%, and 75% year-on-year respectively.
-
The 15th Zhang Zhongjing Medical Culture Festival Traditional Chinese Medicine Industry Development Forum was held in Nanyang
Time of Update: 2021-11-15
Recently, the 15th Zhang Zhongjing Medical Culture Festival and the 9th Zhongjing Forum were held in Nanyang, Henan. Through forums + exhibitions, project signing, and popularization of Chinese medi
-
The east wind of the biopharmaceutical industry has arrived, and the performance of upstream pharmaceutical equipment is expected to continue to increase
Time of Update: 2021-11-15
The industry believes that the east wind of the biopharmaceutical industry has arrived, and the performance of upstream pharmaceutical equipment is expected to continue to increase under the trend of domestic substitution and overseas exports .
-
In October, senior management changes in the pharmaceutical industry were still frequent
Time of Update: 2021-11-15
For example, the Human Resources Department of BeiGene announced to employees that the national head of blood tumor sales, Shi Hao, will leave the company on November 15, 2021, to seek external development opportunities .
-
The fixed asset investment of pharmaceutical companies continues to grow, and the upstream industry is expected to enter a period of long-term steady growth
Time of Update: 2021-11-15
The industry believes that with the continued increase in fixed asset investment by pharmaceutical companies, the pharmaceutical equipment industry is expected to transform from short-term explosive growth to long-term steady growth .
